A Lipid Core Peptide Construct Containing a Conserved Region Determinant of the Group A Streptococcal M Protein Elicits Heterologous Opsonic Antibodies

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2002 Apr 16

PMID 11953422

Citations 17

Authors

Colleen Olive

Michael R Batzloff

Aniko Horvath

Allan Wong

Timothy Clair

Penny Yarwood

Istvan Toth

Michael F Good

Affiliations

Soon will be listed here.

Abstract

The study reported here investigated the immunogenicity and protective potential of a lipid core peptide (LCP) construct containing a conserved region determinant of M protein, defined as peptide J8. Parenteral immunization of mice with LCP-J8 led to the induction of high-titer serum immunoglobulin G J8-specific antibodies when the construct was coadministered with complete Freund's adjuvant (CFA) or administered alone. LCP-J8 in CFA had significantly enhanced immunogenicity compared with the monomeric peptide J8 given in CFA. Moreover, LCP-J8/CFA and LCP-J8 antisera opsonized four different group A streptococcal (GAS) strains, and the antisera did not cross-react with human heart tissue proteins. These data indicate the potential of an LCP-based M protein conserved region GAS vaccine in the induction of broadly protective immune responses in the absence of a conventional adjuvant.

Citing Articles

: Pathogenesis and the Current Status of Vaccines.

Wang J, Ma C, Li M, Gao X, Wu H, Dong W Vaccines (Basel). 2023; 11(9).

PMID: 37766186 PMC: 10534548. DOI: 10.3390/vaccines11091510.

Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.

Iyer V, Sagar V, Toor D, Lyngdoh V, Nongrum G, Kapoor M Cureus. 2023; 14(12):e33146.

PMID: 36721580 PMC: 9884514. DOI: 10.7759/cureus.33146.

Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions.

Root-Bernstein R Int J Mol Sci. 2020; 21(13).

PMID: 32629865 PMC: 7369971. DOI: 10.3390/ijms21134645.

Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.

Herrera A, Van Hove C, Hanson M, Dale J, Tweten R, Huber V PLoS One. 2020; 15(6):e0235139.

PMID: 32574205 PMC: 7310742. DOI: 10.1371/journal.pone.0235139.

Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.

Azuar A, Jin W, Mukaida S, Hussein W, Toth I, Skwarczynski M Vaccines (Basel). 2019; 7(3).

PMID: 31266253 PMC: 6789462. DOI: 10.3390/vaccines7030058.

References

Zeng W, Jackson D, Murray J, Rose K, Brown L . Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens. Vaccine. 1999; 18(11-12):1031-9. DOI: 10.1016/s0264-410x(99)00346-1. View

Brandt E, Sriprakash K, Hobb R, Hayman W, Zeng W, Batzloff M . New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med. 2000; 6(4):455-9. DOI: 10.1038/74719. View

Quinn A, Kosanke S, Fischetti V, Factor S, Cunningham M . Induction of autoimmune valvular heart disease by recombinant streptococcal m protein. Infect Immun. 2001; 69(6):4072-8. PMC: 98471. DOI: 10.1128/IAI.69.6.4072-4078.2001. View

Guilherme L, Oshiro S, Fae K, Cunha-Neto E, Renesto G, Goldberg A . T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun. 2001; 69(9):5345-51. PMC: 98644. DOI: 10.1128/IAI.69.9.5345-5351.2001. View

Wiesmuller K, Bessler W, Jung G . Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe Seylers Z Physiol Chem. 1983; 364(5):593-606. DOI: 10.1515/bchm2.1983.364.1.593. View

Dale J, Beachey E . Multiple, heart-cross-reactive epitopes of streptococcal M proteins. J Exp Med. 1985; 161(1):113-22. PMC: 2187556. DOI: 10.1084/jem.161.1.113. View

Bessen D, Fischetti V . Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun. 1988; 56(10):2666-72. PMC: 259627. DOI: 10.1128/iai.56.10.2666-2672.1988. View

Fischetti V . Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev. 1989; 2(3):285-314. PMC: 358122. DOI: 10.1128/CMR.2.3.285. View

Froude J, Gibofsky A, Buskirk D, Khanna A, Zabriskie J . Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. Curr Top Microbiol Immunol. 1989; 145:5-26. DOI: 10.1007/978-3-642-74594-2_2. View

10.

Deres K, Schild H, Wiesmuller K, Jung G, Rammensee H . In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 1989; 342(6249):561-4. DOI: 10.1038/342561a0. View

11.

Tam J, Lu Y . Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes. Proc Natl Acad Sci U S A. 1989; 86(23):9084-8. PMC: 298438. DOI: 10.1073/pnas.86.23.9084. View

12.

Bessen D, Fischetti V . Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol. 1990; 145(4):1251-6. View

13.

Bronze M, Courtney H, Dale J . Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. J Immunol. 1992; 148(3):888-93. View

14.

Pruksakorn S, Galbraith A, Houghten R, Good M . Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. J Immunol. 1992; 149(8):2729-35. View

15.

Robinson J, Kehoe M . Group A streptococcal M proteins: virulence factors and protective antigens. Immunol Today. 1992; 13(9):362-7. DOI: 10.1016/0167-5699(92)90173-5. View

16.

Schnolzer M, Alewood P, Jones A, Alewood D, Kent S . In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int J Pept Protein Res. 1992; 40(3-4):180-93. DOI: 10.1111/j.1399-3011.1992.tb00291.x. View

17.

Hayman W, Brandt E, Relf W, Cooper J, Saul A, Good M . Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol. 1998; 9(11):1723-33. DOI: 10.1093/intimm/9.11.1723. View

18.

Mora A, Tam J . Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations. J Immunol. 1998; 161(7):3616-23. View

19.

BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M . Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol. 1997; 27(5):1242-53. DOI: 10.1002/eji.1830270528. View

20.

Dale J, Simmons M, Chiang E, Chiang E . Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine. 1996; 14(10):944-8. DOI: 10.1016/0264-410x(96)00050-3. View